ValuEngine upgraded shares of Opexa Therapeutics, Inc. (NASDAQ:ACER) from a sell rating to a hold rating in a report released on Friday.

Opexa Therapeutics (NASDAQ ACER) opened at 9.92 on Friday. Opexa Therapeutics has a 12-month low of $0.96 and a 12-month high of $45.36. The company’s market capitalization is $7.33 million.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

About Opexa Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with's FREE daily email newsletter.